Sanofi

News

GSK sets up Nucala and Dupixent showdown in COPD

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.

Market Access

Sanofi's Dupixent gets FDA nod for chronic hives indication

Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014

News

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

R&D

Type 1 diabetes: The importance of early screening and diagn...

This article was organised, funded, and reviewed by Sanofi.

News

Jean-François Toussaint, Sanofi's global head of vaccines R&D

FDA fast-tracks Sanofi's experimental chlamydia vaccine

Sanofi is preparing to start human testing of its chlamydia vaccine, now fast-tracked by the FDA, that it hopes will be the first to reach the market.

News

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.

GSK sets up Nucala and Dupixent showdown in COPD

Sanofi's Dupixent gets FDA nod for chronic hives indication

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

Type 1 diabetes: The importance of early screening and diagn...

FDA fast-tracks Sanofi's experimental chlamydia vaccine

FDA starts review of Sanofi's MS hope tolebrutinib

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Sanofi

Editor's Picks